Problem gambling among working youth in Southeast Türkiye: predictors and psychological consequences. [PDF]
Düken ME, Suzan ÖK, Günaydın M.
europepmc +1 more source
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Wombs for rent: Exploring the motivations behind Ghanaian Women's decisions to become surrogate mothers. [PDF]
Boafo IM +3 more
europepmc +1 more source
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source
Evaluation of Girls Invest, an economic empowerment intervention to address social and economic risks associated with intimate partner violence among adolescent girls in Ibadan, Nigeria. [PDF]
Fawole OI +8 more
europepmc +1 more source
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić +4 more
wiley +1 more source
'Free From Doubt'? The border between charity and the state in the British National Health Service, 1948-74. [PDF]
Blythe H, Gorsky M.
europepmc +1 more source
Are participants with disability referred for social prescribing? Findings from the English Longitudinal Study of Ageing. [PDF]
Davies LE +6 more
europepmc +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source

